# AbbVie vs Eli Lilly: valuation, size and margins compared

URL: https://funkfolio.com/compare/abbv-vs-lly

> AbbVie ($517.6B, P/E 50.4) and Eli Lilly ($1.26T, P/E 45.9) compared: size, valuation, margins, debt, cash and price change.

---

## AbbVie vs Eli Lilly

AbbVie (ABBV), health care, and Eli Lilly (LLY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Eli Lilly is worth $1.26T on the stock market and AbbVie $517.6B: Eli Lilly is valued at 2.4 times as much. AbbVie trades at 50.4 times earnings and Eli Lilly at 45.9. Over the past year AbbVie's share price has moved +25.9% and Eli Lilly's +39.0%.

### Key facts

- **AbbVie market value:** $517.6B
- **Eli Lilly market value:** $1.26T
- **AbbVie P/E:** 50.4
- **Eli Lilly P/E:** 45.9
- **AbbVie revenue:** $61.2B FY to 2025-12-31
- **Eli Lilly revenue:** $65.2B FY to 2025-12-31
- **Superinvestors holding both:** 11

Market values as of 18 Nov 2026, 01:42 UTC.

AbbVie vs Eli Lilly: every measure side by side

| Measure | AbbVie | Eli Lilly |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $517.6B lower | $1.26T higher |
| Revenue | $61.2B lower | $65.2B higher |
| Earnings | $4.2B lower | $20.6B higher |
| Employees | 57,000 higher | 50,000 lower |
| Total assets | $134B higher | $112.5B lower |
| Valuation |  |  |
| P/E | 50.4 higher | 45.9 lower |
| P/S | 8.5 lower | 19.3 higher |
| P/B | — | 31.3 |
| Dividend yield | 2.35% higher | 0.47% lower |
| Profitability |  |  |
| Operating margin | 24.6% | — |
| Balance sheet |  |  |
| Net assets | -$3.3B lower | $26.5B higher |
| Total liabilities | $137.2B higher | $85.9B lower |
| Total debt | $67.5B higher | $42.5B lower |
| Cash on hand | $5.2B lower | $7.3B higher |
| Price change |  |  |
| Today | -0.59% higher | -1.13% lower |
| 1 year | +25.9% lower | +39.0% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: AbbVie 125.9, Eli Lilly 140.1.

- AbbVie (ABBV)
- Eli Lilly (LLY)

AbbVie and Eli Lilly share prices over one year, rebased to 100: AbbVie ends at 125.9, Eli Lilly at 140.1.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | ABBV | LLY |
| --- | --- | --- |
| Nov 28, 2025 | 97.3 | 105.3 |
| Dec 31, 2025 | 97.6 | 105.2 |
| Jan 30, 2026 | 95.3 | 101.5 |
| Feb 27, 2026 | 99.2 | 103.0 |
| Mar 31, 2026 | 92.9 | 90.0 |
| Apr 30, 2026 | 90.3 | 91.5 |
| May 29, 2026 | 93.0 | 108.2 |
| Jun 30, 2026 | 107.5 | 117.4 |
| Jul 31, 2026 | 107.2 | 112.4 |
| Aug 31, 2026 | 109.6 | 113.2 |
| Sep 30, 2026 | 111.8 | 113.3 |
| Oct 30, 2026 | 126.0 | 138.7 |
| Nov 16, 2026 | 125.9 | 140.1 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (11)

- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.8% / 1.8%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.7% / 1.4%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.5% / 0.7%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.3% / 0.4%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.3% / 0.1%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.2% / 0.4%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 0.1% / 3.4%
- [Jensen team](https://funkfolio.com/gurus/jensen-investment) 0.1% / 4.0%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) 0.1% / 0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1% / 1.6%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) &lt;0.1% / &lt;0.1%

#### AbbVie only (4)

- [Fred DiSanto](https://funkfolio.com/gurus/fred-disanto) 1.5%
- [Lew Sanders](https://funkfolio.com/gurus/lew-sanders) 0.1%
- [Thomas Russo](https://funkfolio.com/gurus/thomas-russo) &lt;0.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) &lt;0.1%

#### Eli Lilly only (17)

- [Primecap team](https://funkfolio.com/gurus/primecap) 6.5%
- [Polen Capital team](https://funkfolio.com/gurus/polen-capital) 4.6%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.9%
- [Cathie Wood](https://funkfolio.com/gurus/cathie-wood) 0.7%
- [Jeffrey Altman](https://funkfolio.com/gurus/jeffrey-altman) 0.6%
- [Temasek](https://funkfolio.com/gurus/temasek) 0.5%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.5%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.4%
- [George Soros](https://funkfolio.com/gurus/george-soros) 0.4%
- [Stanley Druckenmiller](https://funkfolio.com/gurus/stanley-druckenmiller) 0.3%
- [Mario Gabelli](https://funkfolio.com/gurus/mario-gabelli) 0.3%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.3%
- [Frank Sands](https://funkfolio.com/gurus/frank-sands) 0.2%
- [Ron Baron](https://funkfolio.com/gurus/ron-baron) 0.2%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.2%
- [Rob Citrone](https://funkfolio.com/gurus/rob-citrone) 0.1%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": AbbVie / Eli Lilly). [Who owns ABBV](https://funkfolio.com/stock/ABBV/superinvestors) · [Who owns LLY](https://funkfolio.com/stock/LLY/superinvestors)

### More on AbbVie

- [AbbVie (ABBV) stock page](https://funkfolio.com/stock/ABBV)
- [AbbVie market cap](https://funkfolio.com/stock/ABBV/market-cap)
- [AbbVie revenue](https://funkfolio.com/stock/ABBV/revenue)
- [AbbVie P/E ratio](https://funkfolio.com/stock/ABBV/pe-ratio)
- [AbbVie operating margin](https://funkfolio.com/stock/ABBV/operating-margin)
- [AbbVie total debt](https://funkfolio.com/stock/ABBV/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Eli Lilly

- [Eli Lilly (LLY) stock page](https://funkfolio.com/stock/LLY)
- [Eli Lilly market cap](https://funkfolio.com/stock/LLY/market-cap)
- [Eli Lilly revenue](https://funkfolio.com/stock/LLY/revenue)
- [Eli Lilly P/E ratio](https://funkfolio.com/stock/LLY/pe-ratio)
- [Eli Lilly operating margin](https://funkfolio.com/stock/LLY/operating-margin)
- [Eli Lilly total debt](https://funkfolio.com/stock/LLY/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### AbbVie against its closest peers

- [AbbVie vs Johnson & Johnson](https://funkfolio.com/compare/abbv-vs-jnj)
- [AbbVie vs Merck & Co](https://funkfolio.com/compare/abbv-vs-mrk)
- [AbbVie vs UnitedHealth Group](https://funkfolio.com/compare/abbv-vs-unh)

#### Eli Lilly against its closest peers

- [Eli Lilly vs Johnson & Johnson](https://funkfolio.com/compare/jnj-vs-lly)
- [Eli Lilly vs Merck & Co](https://funkfolio.com/compare/lly-vs-mrk)
- [Eli Lilly vs UnitedHealth Group](https://funkfolio.com/compare/lly-vs-unh)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, AbbVie or Eli Lilly?**

By market value, Eli Lilly is the larger: $1.26T against $517.6B for AbbVie. By revenue in its latest fiscal year, Eli Lilly is the larger: $65.2B against $61.2B for AbbVie.

**Which has the higher P/E ratio?**

AbbVie: 50.4, against 45.9 for Eli Lilly. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher dividend yield?**

AbbVie: 2.35%, against 0.47% for Eli Lilly. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which has more debt?**

AbbVie: $67.5B, against $42.5B for Eli Lilly. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both AbbVie and Eli Lilly?**

In their latest 13F filings, Ken Fisher, Larry Robbins, Ken Griffin, David Shaw (founder), Israel Englander, Cliff Asness, Mairs & Power team, Jensen team, Murray Stahl, Rajiv Jain and Bill Nygren hold both.

### Cite this page

Funkfolio, “AbbVie vs Eli Lilly”, data as of 18 November 2026. https://funkfolio.com/compare/abbv-vs-lly

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
